Trade Mark Journal No.2026/023 5 June 2026

UK00004391733 22 May 2026 (5)

MUMDARZY

International priority date claimed: 21 May 2026 (United States of America) (99837343)

Class 5: Pharmaceutical and biological preparations, namely, an orally administered protein kinase C (PKC) inhibitor for treating cancer, tumors, melanoma, and carcinoma; pharmaceutical and biological preparations for use in oncology for medical treatment purposes; pharmaceutical and biological preparations for preventing, diagnosing, treating and managing cancer, tumors, melanoma, and carcinoma; pharmaceutical and biological preparations for preventing, diagnosing, treating and managing metastatic uveal melanoma, primary uveal melanoma, and cutaneous melanoma; therapeutic agents for targeting genetically defined cancers or tumors having GNAQ or GNA11 gene mutations, and destruction of diseased cells, for medical treatment purposes.

Ideaya Biosciences, Inc.

Representative: Page, White & Farrer Limited